RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00030576.xml
CC BY 4.0 · Rev Bras Ginecol Obstet 2021; 43(12): 988-994
DOI: 10.1055/s-0041-1740610
DOI: 10.1055/s-0041-1740610
Febrasgo Position Statement
Use of androgens at different stages of life: reproductive period
Number 11 - December 2021
Key points
-
Although there are several situations that can potentially lead to lower androgen levels, until now is not defined a syndrome or biochemical criteria to diagnose androgen deficiency in women. Benefits of androgen therapy in these situations are controversial.
-
Girls with delayed puberty manifesting primarily as a lack of development of secondary sex characters and primary amenorrhea may be deficient in sex hormone production, including androgen production deficiency.
-
Due to surgical menopause and premature ovarian failure, androgen levels may be reduced compared to age-matched normal controls.
-
Young women with hypopituitarism, anorexia nervosa, and adrenal insufficiency may have lower serum androgen levels.
-
The use of androgens and anabolic steroids for aesthetic purposes has increased considerably due to issues related to the cult of the body and beauty. However, this is associated with undesirable and potentially irreversible aesthetic manifestations, in addition to an increase in morbidity.
The National Specialty Commission on Gynecology Endocrinology of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.
Publikationsverlauf
Artikel online veröffentlicht:
21. Dezember 2021
© 2021. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Davis SR. Androgen therapy in women, beyond libido. Climacteric 2013; ;16 Suppl 1: 18-24 DOI: 10.3109/13697137.2013.801736.
- 2 Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM. et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999; 44 (12) 1012-1020
- 3 Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH. et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (10) 3489-510 DOI: 10.1210/jc.2014-2260.
- 4 Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res 2005; 17 (05) 399-408 DOI: 10.1038/sj.ijir.3901334.
- 5 Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC. Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids 2013; 78 (01) 96-101 DOI: 10.1016/j.steroids.2012.10.010.
- 6 Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol 1999; 69 (1-6): 481-485 DOI: 10.1016/s0960-0760(99)00070-9.
- 7 Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 2010; 121 (3-5): 513-519 DOI: 10.1016/j.jsbmb.2010.03.032.
- 8 Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR. et al. American association of clinical endocrinologists and American college of endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr Pract 2015; 21 (09) 1066-1073 DOI: 10.4158/EP14434.PS.
- 9 Simpson ER. Aromatization of androgens in women: current concepts and findings. Fertil Steril 2002; 77 Suppl 4: S6-10 DOI: 10.1016/s0015-0282(02)02984-9.
- 10 Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005; 294 (01) 91-6 DOI: 10.1001/jama.294.1.91.
- 11 Sawyer SM, Azzopardi PS, Wickremarathne D, Patton GC. The age of adolescence. Lancet Child Adolesc Health. 2018; 2 (03) 223-8 DOI: 10.1016/S2352-4642(18)30022-1.
- 12 Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P. et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011; 76 (1-2): 177-182 DOI: 10.1016/j.steroids.2010.10.010.
- 13 Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986; 15 (02) 213-28 DOI: 10.1016/s0300-595x(86)80021-4.
- 14 Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80 (04) 1429-1430 DOI: 10.1210/jcem.80.4.7714119.
- 15 Weiss RV, Hohl A, Athayde A, Pardini D, Gomes L, Oliveira M. et al. Testosterone therapy for women with low sexual desire: a position statement from the Brazilian society of endocrinology and metabolism. Arch Endocrinol Metab 2019; 63 (03) 190-198 DOI: 10.20945/2359-3997000000152.
- 16 Vanderschueren D, Vandenput L, Boonen S. Reversing sex steroid deficiency and optimizing skeletal development in the adolescent with gonadal failure. Endocr Dev 2005; 8: 150-165 DOI: 10.1159/000084100.
- 17 Mason KA, Schoelwer MJ, Rogol AD. Androgens during infancy, childhood, and adolescence: physiology and use in clinical practice. Endocr Rev 2020; 41 (03) bnaa003 DOI: 10.1210/endrev/bnaa003.
- 18 Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in turner syndrome: a pilot study. J Clin Endocrinol Metab 2009; 94 (12) 4820-4827 DOI: 10.1210/jc.2009-0514.
- 19 Rosenfeld RG, France J, Attie KM, Brasel JA, Burstein S, Cara JF. et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992; 121 (01) 49-55 DOI: 10.1016/s0022-3476(05)82540-5.
- 20 Bilger M, Speraw S, LaFranchi SH, Hanna CE. Androgen replacement in adolescents and young women with hypopituitarism. J Pediatr Endocrinol Metab 2005; 18 (04) 355-362 DOI: 10.1515/jpem.2005.18.4.355.
- 21 Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update 2012; 18 (04) 405-419 DOI: 10.1093/humupd/dms013.
- 22 Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open 2017; 2017 (02) hox007 DOI: 10.1093/hropen/hox007.
- 23 Vegunta S, Kling JM, Kapoor E. Androgen therapy in women. J Womens Health 2020; 29 (01) 57-64 DOI: 10.1089/jwh.2018.7494.
- 24 Miller KK, Biller BM, Beauregard C, Lipman JG, Jones J, Schoenfeld D. et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006; 91 (05) 1683-1690 DOI: 10.1210/jc.2005-2596.
- 25 Miller KK, Lawson EA, Mathur V, Wexler TL, Meenaghan E, Misra M. et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 2007; 92 (04) 1334-1339 DOI: 10.1210/jc.2006-2501.
- 26 Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M. et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92 (10) 3912-3922 DOI: 10.1210/jc.2007-0685.
- 27 Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ. et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009; 94 (10) 3676-3681 DOI: 10.1210/jc.2009-0672.
- 28 Castinetti F, Guignat L, Bouvattier C, Samara-Boustani D, Reznik Y. Group 4: replacement therapy for adrenal insufficiency. Ann Endocrinol (Paris) 2017; 78 (06) 525-534 DOI: 10.1016/j.ando.2017.10.007.
- 29 Miller KK, Meenaghan E, Lawson EA, Misra M, Gleysteen S, Schoenfeld D. et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2011; 96 (07) 2081-2088 DOI: 10.1210/jc.2011-0380.
- 30 Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005; 90 (03) 1428-1433 DOI: 10.1210/jc.2004-1181.
- 31 Kimball A, Schorr M, Meenaghan E, Bachmann KN, Eddy KT, Misra M. et al. A randomized placebo-controlled trial of low-dose testosterone therapy in women with anorexia nervosa. J Clin Endocrinol Metab 2019; 104 (10) 4347-4355 DOI: 10.1210/jc.2019-00828.
- 32 Hanley SantosG, Coomber R. The risk environment of anabolic-androgenic steroid users in the UK: examining motivations, practices and accounts of use. Int J Drug Policy 2017; 40: 35-43 DOI: 10.1016/j.drugpo.2016.11.005.
- 33 Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008; 154 (03) 502-521 DOI: 10.1038/bjp.2008.165.
- 34 Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24 (05) 383-398 DOI: 10.1016/j.annepidem.2014.01.009.
- 35 Anderson LJ, Tamayose JM, Garcia JM. Use of growth hormone, IGF-I, and insulin for anabolic purpose: pharmacological basis, methods of detection, and adverse effects. Mol Cell Endocrinol 2018; 464: 65-74 DOI: 10.1016/j.mce.2017.06.010.
- 36 Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol 2015; 173 (02) R47-58 DOI: 10.1530/EJE-15-0080.
- 37 Gruber AJ, Pope Jr. HG. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom 2000; 69 (01) 19-26 DOI: 10.1159/000012362.
- 38 Rasmussen JJ, Schou M, Selmer C, Johansen ML, Gustafsson F, Frystyk J. et al. Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clin Endocrinol (Oxf) 2017; 87 (03) 249-56 DOI: 10.1111/cen.13372.
- 39 de Castro CoelhoF, Barros C. The potential of hormonal contraception to influence female sexuality. Int J Reprod Med 2019; 2019: 9701384 DOI: 10.1155/2019/9701384.